NASDAQ:RAREUltragenyx Pharmaceutical Stock Price, Forecast & News

Ultragenyx Pharmaceutical's stock was trading at $45.35 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RARE shares have increased by 54.2% and is now trading at $69.92. View which stocks have been most impacted by Coronavirus.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) issued its earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($1.91) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.68) by $0.23. The biopharmaceutical company had revenue of $36.31 million for the quarter, compared to analysts' expectations of $36.74 million. Ultragenyx Pharmaceutical had a negative net margin of 348.78% and a negative return on equity of 60.65%. The firm's quarterly revenue was up 99.8% on a year-over-year basis. During the same quarter last year, the business earned ($1.82) earnings per share. View Ultragenyx Pharmaceutical's earnings history.

13 brokerages have issued 1 year price targets for Ultragenyx Pharmaceutical's shares. Their forecasts range from $66.00 to $87.00. On average, they anticipate Ultragenyx Pharmaceutical's share price to reach $77.09 in the next year. This suggests a possible upside of 10.3% from the stock's current price. View analysts' price targets for Ultragenyx Pharmaceutical.

Media coverage about RARE stock has trended somewhat negative recently, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ultragenyx Pharmaceutical earned a news sentiment score of -1.5 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutUltragenyx Pharmaceutical.

Some companies that are related to Ultragenyx Pharmaceutical include Alnylam Pharmaceuticals (ALNY), Merck KGaA (MKGAF), Teva Pharmaceutical Industries (TEVA), GRIFOLS S A/S (GRFS), Beigene (BGNE), GALAPAGOS NV/S (GLPG), Catalent (CTLT), Sarepta Therapeutics (SRPT), Ono Pharmaceutical (OPHLF), Mylan (MYL), Horizon Therapeutics (HZNP), Elanco Animal Health (ELAN), Dr.Reddy's Laboratories (RDY), Ionis Pharmaceuticals (IONS) and Perrigo (PRGO). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Gilead Sciences (GILD), Exelixis (EXEL), TG Therapeutics (TGTX), Portola Pharmaceuticals (PTLA), Sangamo Therapeutics (SGMO), AbbVie (ABBV), Crispr Therapeutics (CRSP), GALAPAGOS NV/S (GLPG), GW Pharmaceuticals PLC- (GWPH) and Intercept Pharmaceuticals (ICPT).

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

Ultragenyx Pharmaceutical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Capital Research Global Investors (11.02%), Capital International Investors (10.28%), BlackRock Inc. (7.88%), Federated Hermes Inc. (6.73%), State Street Corp (3.74%) and Alliancebernstein L.P. (2.37%). Company insiders that own Ultragenyx Pharmaceutical stock include Emil D Kakkis, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Theodore Alan Huizenga and William Aliski. View institutional ownership trends for Ultragenyx Pharmaceutical.

RARE stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, First Trust Advisors LP, BlackRock Inc., Alliancebernstein L.P., Morgan Stanley, Morgan Stanley, Cinctive Capital Management LP, and AXA. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, and Theodore Alan Huizenga. View insider buying and selling activity for Ultragenyx Pharmaceutical.

RARE stock was bought by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Bank of New York Mellon Corp, Capital Research Global Investors, Fred Alger Management LLC, Capital International Investors, Castleark Management LLC, Geode Capital Management LLC, and Rhenman & Partners Asset Management AB. View insider buying and selling activity for Ultragenyx Pharmaceutical.

Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RARE stock can currently be purchased for approximately $69.92.

Ultragenyx Pharmaceutical has a market capitalization of $4.17 billion and generates $103.71 million in revenue each year. The biopharmaceutical company earns $-402,730,000.00 in net income (profit) each year or ($7.36) on an earnings per share basis.

The official website for Ultragenyx Pharmaceutical is www.ultragenyx.com.

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at 415-483-8800 or via email at [email protected]